Lead Causes Of Acid Reflux

🔥+ Lead Causes Of Acid Reflux 07 Jul 2020 Heartburn is the most common symptom of GERD. What causes GERD? GERD happens when gastric acid from your stomach backs up into your food pipe ( ...

Lead Causes Of Acid Reflux This is some general advice if you are going to be following an acid reflux diet. ... Dairy - Milk shake, sour cream, ice cream and regular cottage cheese

Gerd Medical Diseas Skip to Main content
ScienceDirect
Lead Causes Of Acid Reflux 9 Home Remedies (⭐️ Acid Reflux) | Lead Causes Of Acid Reflux Remedy Reliefhow to Lead Causes Of Acid Reflux for RegisterSign in

Enzyme Supplementation

Elias Westermarck, in Canine and Feline Gastroenterology, 2013

Pancreatic enzyme replacement therapy was first attempted in human medicine at the turn of the twentieth century and it was shown that nutritional status could be significantly improved with such therapies. One challenge to this therapy is the sensitivity of pancreatic enzymes to gastric acid. Amylase and lipase are the most susceptible and are destroyed at a pH below 4.5. Trypsin can withstand a pH of 3.5, thus remaining unaffected by most pH conditions in the stomach. In humans, only 17% of ingested lipase can be recovered intact from the duodenum.2 To improve passage of pancreatic enzymes through the acidic environment of the stomach, pharmaceutical companies have developed porcine, enteric-coated pancreatic enzyme preparations. The manufacturing process must be gentle to ensure that enzymes are not destroyed. Although much is already known about pancreatic enzyme supplementation, modern replacement therapy has significant room for improvement. Despite adequate enzyme supplementation, digestion capacity does not return to normal in humans or dogs with exocrine pancreatic insufficiency (EPI). Only a small portion of the orally administered enzyme is delivered intact and functional to the small intestine.1 For maximum digestive efficiency, pancreatic enzyme preparations should be formulated to (a) protect acid-labile enzyme from gastric inactivation, (b) provide concomitant gastric emptying of the enzyme with the ingested meal, and (c) deliver maximal enzyme activity to the proximal duodenum. To fulfill these criteria, formulation of a sustained-release preparation of pancreatic extract that releases enzymes over a prolonged period of time to a site favorable for their function would be highly desirable. Unfortunately, this preparation is not yet commercially available.3

Read full chapter
URL: https://www.sciencedirect.com/science/article/pii/B978141603661600047X

Congenital disorders of the pancreas

Lead Causes Of Acid Reflux Heartburn (👍 Best Drinks For) | Lead Causes Of Acid Reflux Nighttimehow to Lead Causes Of Acid Reflux for Ewen M. Harrison, Rowan for 1 last update 07 Jul 2020 W. Parks, in Ewen M. Harrison, Rowan W. Parks, in Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set (Sixth Edition), 2017

IV Supplementary Diagnosis

The following findings strongly suggest the existence of pancreaticobiliary maljunction.

Elevated Amylase Levels in Bile

Pancreatic enzymes, especially amylase, in the bile within the bile duct and gallbladder obtained immediately after laparotomy (endoscopically or percutaneously), are generally at extremely high levels. However, levels close to or below the normal serum value are occasionally observed in patients with pancreaticobiliary maljunction.

Clinical features similar to pancreaticobiliary maljunction, including elevation of pancreatic enzymes in bile, are observed in some cases with a relatively long common channel, showing the effect of the sphincter on the pancreaticobiliary junction.

Extrahepatic Bile Duct Dilation

Pancreaticobiliary maljunction includes one type that is associated with bile duct dilation (congenital biliary dilation), and another that is not (pancreaticobiliary dilation without biliary dilation). When cystic, fusiform, or cylindrical dilation is detected in the extrahepatic bile duct, careful investigations are needed to determine whether pancreaticobiliary maljunction is present.

Standard values for the maximum diameter of the common bile duct at each age are useful for diagnosing pancreaticobiliary maljunction with or without biliary dilation.

Read full chapter
URL: https://www.sciencedirect.com/science/article/pii/B9780323340625000534

Lead Causes Of Acid Reflux Acid Reflux (🔥 Natural Remedies For) | Lead Causes Of Acid Reflux Acidityhow to Lead Causes Of Acid Reflux for Gastrointestinal Complications in the Postoperative Period

Lead Causes Of Acid Reflux Natural Remedies For (☑ Natural Heartburn Remedies) | Lead Causes Of Acid Reflux Testshow to Lead Causes Of Acid Reflux for JOHN A. EVANS MD, ... LAWRENCE S. FRIEDMAN MD, in Medical Management of the Surgical Patient (Third Edition), 2008

MANAGEMENT

Pancreatic enzyme replacement (e.g., pancrelipase, two to three tablets orally three times a day with meals and one or two with snacks) may improve the maldigestion and malnutrition that often accompany chronic pancreatitis. Frequently, chronic pancreatitis may lead to narcotic addiction because of a large requirement for analgesic medications to control chronic pain. Medication doses required for induction of anesthesia may be increased in such patients. When there is evidence of pancreatic duct obstruction with proximal dilation, the chronic pain of pancreatitis may respond to a drainage operation such as a longitudinal pancreaticojejunostomy, sometimes with resection of the pancreatic head. Similarly, endoscopic or surgical decompression of a large pseudocyst may result in pain relief. Pancreatic enzyme supplementation with an uncoated formulation to suppress pancreatic secretion, often given with oral bicarbonate, an H2-receptor antagonist, or a proton pump inhibitor, may lead to pain relief in some patients. Total or subtotal pancreatectomy as a means of pain control is associated with unpredictable results. Neurolysis of the celiac ganglion is less effective in relieving the pain of chronic pancreatitis than the pain of pancreatic cancer.

Read full chapter
URL: https://www.sciencedirect.com/science/article/pii/B978141602385250010X

Pancrelipase

Mark G. Papich DVM, MS, DACVCP, in Saunders Handbook of Veterinary Drugs (Fourth Edition), 2016

Pharmacology and mechanism of action

Lead Causes Of Acid Reflux Heartburn Relief (👍 Heartburn Relief) | Lead Causes Of Acid Reflux 9 Home Remedieshow to Lead Causes Of Acid Reflux for Pancreatic enzyme. Pancrelipase provides lipase, amylase, and protease. Pancrelipase is a mixture of enzymes (lipase, amylase, and protease) obtained from the pancreas of pigs. These enzymes enhance digestion of fats, proteins, and starches for 1 last update 07 Jul 2020 in the upper duodenum and jejunum. They are more active in an alkaline environment. There are coated and uncoated tablets. The uncoated tablets are not as bioavailable because degradation may occur in the acid of the stomach. Each milligram contains 24 units lipase, 100 units amylase, and 100 units of protease activity.Pancreatic enzyme. Pancrelipase provides lipase, amylase, and protease. Pancrelipase is a mixture of enzymes (lipase, amylase, and protease) obtained from the pancreas of pigs. These enzymes enhance digestion of fats, proteins, and starches in the upper duodenum and jejunum. They are more active in an alkaline environment. There are coated and uncoated tablets. The uncoated tablets are not as bioavailable because degradation may occur in the acid of the stomach. Each milligram contains 24 units lipase, 100 units amylase, and 100 units of protease activity.

Read full chapter
URL: https://www.sciencedirect.com/science/article/pii/B9780323244855004368

Pancreatic Insufficiency☆

T.E. Adrian, in Reference Module in for 1 last update 07 Jul 2020 Biomedical SciencesReference Module in Biomedical Sciences, 2014

Introduction

Pancreatic enzymes, and the high-bicarbonate concentration of the pancreatic juice in which these zymogens are secreted, are essential for the normal intraluminal digestion of dietary macronutrients. The pancreas has a vast capacity to produce enzymes for digestion. However, when lipase activity in the small bowel falls below 10% of normal, undigested nutrients and in particular fat, enter the colon and are lost in the stool (steatorrhea).Unabsorbed nutrients enter the colon and trigger osmotic diarrhea to add to the fatty stool weight. Bacterial fermentation of these nutrients increases flatus.

Read full chapter
URL: https://www.sciencedirect.com/science/article/pii/B9780128012383052077

Other Clinical Manifestations

Philip Robinson, in Pediatric Respiratory Medicine (Second Edition), 2008

Lead Causes Of Acid Reflux 6 Natural Remedies (☑ Heartburn Symptoms) | Lead Causes Of Acid Reflux To Eathow to Lead Causes Of Acid Reflux for Pancreatic Enzyme Therapy

Pancreatic enzyme replacement therapy is introduced once clinical evidence of pancreatic insufficiency is confirmed. Due to the progressive nature of CF, individuals who are pancreatic sufficient at diagnosis require periodic assessment of pancreatic function. This can be inferred by knowledge of their genotype and class of their CFTR mutation.

Most pancreatic enzyme replacement guidelines71 recommend using a dietary fat–based dosage to link consumption of grams of fat to units of lipase in the capsules or body weight as a basis and then individualizing the dose based on assessments of efficacy. It is recommended that when commencing pancreatic enzyme replacement therapy (PERT), the minimum dose in the recommended range is used.71

Lead Causes Of Acid Reflux GERD Diet (⭐️ 7 Natural GERD) | Lead Causes Of Acid Reflux Quick Reliefhow to Lead Causes Of Acid Reflux for Redistribution of pancreatic enzyme capsules over the day, based on the fat content of the foods consumed, has been shown to lead to a significant improvement in the coefficient of fat absorption and hence absorbed energy.72 Fat-based dosing may assist individuals with CF in achieving the high-energy, high-fat diet recommended by helping to improve patient knowledge of food composition. Patient knowledge, particularly of fat, has been shown to be poor.73

Minimum effective doses are recommended in order to decrease the risk of fibrosing colonopathy, which continues to be found in association with “enzyme overdosing.” for 1 last update 07 Jul 2020 7474 An upper limit of 10,000 IU lipase/kg body weight/day has been recommended to reduce the risk of fibrosing colonopathy. An audit of use of PERT in patients attending CF centers in the United Kingdom (1999-2000) demonstrated that patients on preparations containing 10,000 or 25,000 IU lipase per capsule commonly exceeded recommendation. the 1 last update 07 Jul 2020 7575 Further, they reported that use of high-strength PERT increased the risk of overdosing, with two thirds of patients in this group exceeding recommendations compared with one third in the standard-strength preparation group.

Patients with exocrine pancreatic insufficiency require long-term replacement therapy with pancreatic enzyme supplements. Although originally available as powdered pancreatic extracts, most, if not all, pancreatic extracts are prepared today as enteric-coated microsphere or microtablet preparations. The introduction of enteric-coated preparations has increased significantly the efficiency of these enzymes, which work maximally at an alkaline pH and thus, unprotected, would be exposed to significant degradation in their passage through the stomach. In infancy, the capsules containing the microspheres can be opened and administered in a soft nonalkaline food such as applesauce. In infants, enzyme dosing can be based on food intake, starting with 2000 to 4000 lipase units/120 mL formula or per breastfeeding.Lead Causes Of Acid Reflux Heartburn Home Remedies (⭐️ Diet Changes For) | Lead Causes Of Acid Reflux Cure Your Acid Refluxhow to Lead Causes Of Acid Reflux for 76 Beyond infancy, weight-based dosing is more practical. It should begin with 1000 lipase units/kg per meal for children younger than 4 years and 500 lipase units/kg for those older than 4 years.76 Enzyme dosage expressed as lipase units/kg per meal should be decreased in older patients because they tend to ingest less fat per kilogram of body weight. Usually, half the standard dose is given with snacks. There is great interindividual variation in response to enzymes, so a range of dosages is recommended, based on stool pattern and weight gain. Dosages greater than 2500 lipase units/kg per meal or 10,000 lipase units/kg per day should be used with caution and only if they are documented to be effective by 3-day fecal fat measure. After initiation of enzyme therapy, there should be almost immediate reduction in stool frequency and degree of steatorrhea, improvement in abdominal symptoms, and decrease in appetite. Most patients are able to achieve a coefficient of fat absorption greater than 85%.

Variations in enzyme requirements and patient response may be related to endogenous enzyme output, type of diet, microsphere size, gastric emptying time of microspheres, postprandial duodenal pH, and bile salt concentration.Lead Causes Of Acid Reflux Natural Remedies For (☑ 10 Home Remedies) | Lead Causes Of Acid Reflux Foods For Acid Refluxhow to Lead Causes Of Acid Reflux for 77 Failure of enzyme release secondary to a low postprandial duodenal pH is probably the major factor leading to inefficient enzyme function.Lead Causes Of Acid Reflux 6 Ways To Get Relief During (🔴 10 Foods) | Lead Causes Of Acid Reflux What Is The Besthow to Lead Causes Of Acid Reflux for for 1 last update 07 Jul 2020 7878 In patients who have persistent steatorrhea (>10% fecal fat loss) despite apparently adequate enzyme dosage, addition of an acid-reducing agent may lead to significant enhancement of fat absorption.Lead Causes Of Acid Reflux Causes (☑ Heartburn Relief Foods) | Lead Causes Of Acid Reflux Treatmenthow to Lead Causes Of Acid Reflux for 79–82

Some patients on high-dose enzyme therapy have ongoing abdominal symptoms unrelated to exocrine pancreatic deficiency.83 In such cases, 72-hour fecal fat measure and evaluation for concurrent gastrointestinal disorders (lactose malabsorption, giardiasis, bacterial overgrowth, celiac disease, Crohn disease) are indicated. The development of constipation in a patient who is taking enzymes may be an indication for increased enzymes. A misguided reduction in enzyme dosage in this situation may precipitate an episode of distal intestinal obstruction syndrome (DIOS).

The most significant complication of pancreatic enzymes is fibrosing colonopathy, a condition associated with the use of high daily doses of enzyme. This diagnosis should be considered in patients who have symptoms of obstruction, bloody diarrhea, chylous ascites, or the combination of abdominal pain with ongoing diarrhea or poor weight gain.84 Patients at highest risk are those who are younger than 12 years, have taken more than 6000 lipase units/kg per meal for longer than 6 months, or have a history of gastrointestinal surgery or complications.74,85 Most cases involve the ascending colon, but pancolonic involvement can occur.84 A barium enema is the most reliable diagnostic measure. Colonic shortening, focal or extensive narrowing, and a lack of distensibility are highly suggestive. Diagnosis is confirmed by biopsy. Bowel wall thickening, which may be a precursor of stricture formation, may be detected by ultrasonography. Most cases of fibrosing colonopathy require hemicolectomy. for 1 last update 07 Jul 2020 8686

Read full chapter
URL: https://www.sciencedirect.com/science/article/pii/B9780323040488500670

CYSTIC FIBROSIS

R.W. Shepherd, in Encyclopedia of Food Sciences and Nutrition (Second Edition), 2003

Pancreatic Enzyme Replacement Therapy

Pancreatic enzyme replacement therapy (PERT) needs to be tailored to individual requirements and is required in about 85% of CF patients, according to the amount of food (particularly fat) eaten and the degree of malabsorption. It is appropriate to assess quantitatively the degree of malabsorption and the ability of the therapy to correct this. Some measures to improve the efficacy of PERT have been a recent area of study in CF, as conventional preparations rarely fully optimize absorption. The objectives of PERT include correction of maldigestion, elimination of symptoms and signs of malabsorption, and sustaining normal nutrition.

A bewildering number of pancreatic enzyme preparations are commercially available in the form of tablets, capsules, enteric-coated microspheres, granules, and powders. Some products have not been designed specifically for the treatment of exocrine pancreatic insufficiency, but for patients with unspecified abdominal pain. Some contain bile salts; in general these should be avoided in patients with pancreatic insufficiency because high concentrations of bile salts may aggravate diarrhea. Preparations that are protected against peptic acid inactivation are preferable to unprotected preparations: unprotected ingested enzymes are degraded to a significant degree as a result of increased gastric acidity, and lowered duodenal pH secondary to depressed bicarbonate secretion for the pancreas. The lipase content is the most important determinant of the effectiveness of these products. Between 80% and 90% of unprotected ingested lipase and trypsin is inactivated in the stomach. It was thought that PERT was complication-free, but excessive doses have been associated with renal calculi, and prolonged excessive dosages with serious fibrosing colonopathy. Guidelines for the safe correct use of PERT have been published. In the UK, the Committee of Safety of Medicines suggests doses of no more than 10 000 u lipase kg−1 day−1.

It has been calculated that, in an adult, assuming there is no inactivation of the 1 last update 07 Jul 2020 enzymes in the stomach, approximately 30 000 IU of lipase is required to be delivered to the duodenum with an average meal containing about 6 g of fat for normal digestion. In children approximately 500–4000 IU is required per gram of fat ingested. The distribution of fat content of different meals and the mixing enzymes with food in the duodenum seems to be important. Granulated preparations or microspheres are better than tablets in that they enable higher enzyme activities to reach the duodenum and mix with the food. The majority of enzyme preparations contain between 5000 and 20 000 IU of lipase. It can thus be calculated that, for the average adult, if some defence against gastric inactivation is provided and there is an adequate enzyme–meal mix, between 2 and 10 capsules are required per meal to control steatorrhea. Studies in children comparing conventional tablet enzyme therapy to enteric-coated microspheres of pancrelipase have shown that significantly less steatorrhea and azotorrhea occur with the use of the microsphere preparation. In addition, there is an improvement in compliance because significantly fewer capsules are required. Irrespective of the preparation used, there is good evidence that the enzymes need to be delivered appropriately and dispersed evenly throughout a meal, in order to achieve maximum exposure of food to the ingested enzymes.It has been calculated that, in an adult, assuming there is no inactivation of enzymes in the stomach, approximately 30 000 IU of lipase is required to be delivered to the duodenum with an average meal containing about 6 g of fat for normal digestion. In children approximately 500–4000 IU is required per gram of fat ingested. The distribution of fat content of different meals and the mixing enzymes with food in the duodenum seems to be important. Granulated preparations or microspheres are better than tablets in that they enable higher enzyme activities to reach the duodenum and mix with the food. The majority of enzyme preparations contain between 5000 and 20 000 IU of lipase. It can thus be calculated that, for the average adult, if some defence against gastric inactivation is provided and there is an adequate enzyme–meal mix, between 2 and 10 capsules are required per meal to control steatorrhea. Studies in children comparing conventional tablet enzyme therapy to enteric-coated microspheres of pancrelipase have shown that significantly less steatorrhea and azotorrhea occur with the use of the microsphere preparation. In addition, there is an improvement in compliance because significantly fewer capsules are required. Irrespective of the preparation used, there is good evidence that the enzymes need to be delivered appropriately and dispersed evenly throughout a meal, in order to achieve maximum exposure of food to the ingested enzymes.

The success of enzyme therapy is assessed by bowel symptoms, quantitative absorptive tests, such as fecal fat analysis, and the maintenance of normal nutrition. In children, assessment of growth is also essential. Azotorrhea is more frequently abolished by pancreatic enzyme supplements than is steatorrhea, possibly because trypsin secretion is better preserved than lipase secretion in pancreatic insufficiency, and because trypsin is not inactivated by acid but only by pepsin. Poor response to pancreatic enzyme preparations may result from poor compliance, inappropriate timing of administration, the presence of another condition causing steatorrhea (e.g., bacterial overgrowth), or the use of an unprotected, acid-sensitive enzyme preparation.

Read full chapter
URL: https://www.sciencedirect.com/science/article/pii/B012227055X003199

Gastrointestinal System

Robert G. Carroll for 1 last update 07 Jul 2020 PhD, in Robert G. Carroll PhD, in Elsevier's Integrated Physiology, 2007

Exocrine Pancreatic Enzymes

Pancreatic enzymes are essential for the normal digestion and absorption of lipids, proteins, and carbohydrates. The exocrine pancreas secretes both a bicarbonate-rich solution and a variety of digestive enzymes, including proteases, lipases, and amylases. Columnar epithelial cells of the pancreatic ducts secrete the aqueous bicarbonate component. Lead Causes Of Acid Reflux Foods To Eat And Avoid (👍 Natural Remedies) | Lead Causes Of Acid Reflux 10 Easyhow to Lead Causes Of Acid Reflux for Pancreatic acinar cells secrete the digestive enzymes. Pancreatic secretions are carried to the duodenum by the pancreatic duct. The epithelia of the pancreatic ducts are relatively permeable to water but impermeable to large molecules. Once in the lumen of the duodenum, pancreatic HCO3 acts to neutralize duodenal chyme.

Pancreatic proteases are secreted in an inactive zymogen form, along with a trypsin inhibitor, to prevent premature activation. Pancreatic trypsinogen is activated by duodenal enterokinase to become trypsin. Trypsin then acts on zymogens to form more trypsin (autocatalysis), chymotrypsin, and carboxypeptidases. α-Amylase is secreted in an active form, as are lipases, ribonuclease, and deoxyribonuclease.

The water component of pancreatic secretion is produced at a rate of about 1 L/day. The initial ion composition of this fluid is similar to that of plasma except for the higher HCO3 and lower Cl content. In the pancreatic duct, some HCO3 is exchanged for Cl by an apical membrane transporter, so HCO3 concentration of pancreatic secretion is low at low flow rates. Secretin stimulates an increase in both HCO3 concentration and the volume of pancreatic secretion. Regulation of pancreatic water and bicarbonate secretion is accomplished by both secretin and neural control, primarily in response to the presence of acid and digestive contents in the lumen of the duodenum (Fig. 12-9).

PHARMACOLOGY

Lead Causes Of Acid Reflux Simples Steps (☑ 7 Natural) | Lead Causes Of Acid Reflux 10 Foods To Eathow to Lead Causes Of Acid Reflux for Inhibition of Gastric Acid Secretion

Inhibition of gastric acid secretion can be accomplished by blocking the normal stimulation pathways or by directly inhibiting the proton pump. There are three different normal stimulators of gastric for 1 last update 07 Jul 2020 acid secretion: histamine, acetylcholine, and gastrin. H2 antagonists (cimetidine), muscarinic antagonists (atropine), and gastrin receptor CCK-B antagonists can all block gastric acid secretion. Drugs such as omeprazole inactivate the H+/K+ proton pump directly and are referred to as proton pump inhibitors.Inhibition of gastric acid secretion can be accomplished by blocking the normal stimulation pathways or by directly inhibiting the proton pump. There are three different normal stimulators of gastric acid secretion: histamine, acetylcholine, and gastrin. H2 antagonists (cimetidine), muscarinic antagonists (atropine), and gastrin receptor CCK-B antagonists can all block gastric acid secretion. Drugs such as omeprazole inactivate the H+/K+ proton pump directly and are referred to as proton pump inhibitors.

Cholecystokinin, released in response to amino acids and fatty acids in the duodenum, increases secretion of the pancreatic digestive enzymes necessary for digestion of all food groups. There is mutual potentiation of CCK and secretin.

Vagal parasympathetic nerves are necessary for the full pancreatic secretory response. Parasympathetic nerve activity enhances both enzyme and aqueous secretion. Sympathetic nerve activity inhibits pancreatic secretion, perhaps secondary to the decrease in pancreatic blood flow.

Read full chapter
URL: https://www.sciencedirect.com/science/article/pii/B9780323043182500182

Functional Assessment of Gastrointestinal Health

Lead Causes Of Acid Reflux List Of (☑ Common Heartburn Triggers) | Lead Causes Of Acid Reflux Treatments Forhow to Lead Causes Of Acid Reflux for the 1 last update 07 Jul 2020 R. Jaffe, in R. Jaffe, in Bioactive Food as Dietary Interventions for Liver and Gastrointestinal Disease, 2013

2.4.2.1 Low enzyme levels

Lead Causes Of Acid Reflux Home Remedies For (☑ Heartburn Relief) | Lead Causes Of Acid Reflux 13 Surprisinghow to Lead Causes Of Acid Reflux for When pancreatic enzyme levels decrease, the cause is usually functional hypochlorhydria. Symptoms such as bloating, heartburn, constipation, diarrhea, insomnia, muscle aches, pain, and skin conditions that occur when the skin is used as an accessory ouster of excretes. Causal factors include an abundance of processed food in the diet and overuse of medications such as antibiotics and painkillers.

Enzyme insufficiencies can be caused by genetic conditions or low levels of probiotics, which result in a lack of the enzymes needed for digestion. Two potential solutions include the supplementation of probiotics (described in the section ‘Lead Causes Of Acid Reflux Treatment (👍 Nighttime) | Lead Causes Of Acid Reflux Testshow to Lead Causes Of Acid Reflux for Profile: Maldigestion and Enteropathy’) and enzymes (Domínguez-Muñoz et al., 2005). We find implantable probiotics, unprocessed dietary fiber a whole food-based immunocompatible diet to restore digestive and detox competence that in turn restores neuro-hormonal balance of the immune system.

Read full chapter
URL: https://www.sciencedirect.com/science/article/pii/B9780123971548000026

The Liver, Biliary Tract, and Exocrine Pancreas

Sharon A. Center, in Small Animal Pediatrics, 2011

Pancreatic Exocrine Insufficiency

Exocrine pancreatic enzymes provide essential digestive functions such that loss of 90% of this capacity leads to maldigestion and exocrine pancreatic insufficiency (EPI) syndrome. Subclinical and clinical EPI syndromes have been characterized in dogs and are relatively rare in cats. Dogs with subclinical EPI have clinical signs masked by continued small-volume pancreatic enzyme secretion or digestion facilitated by alternative mechanisms (lingual or gastric lipases, gastric pepsins, intestinal mucosal esterases, and peptidases). Causes of canine EPI for 1 last update 07 Jul 2020 include pancreatic acinar atrophy (PAA; an apparent autoimmune lymphocytic inflammatory disorder), chronic pancreatitis, and pancreatic neoplasia. By far, PAA is most common and can affect dogs within the first year of life, although it usually becomes overt within the first 3 years. Long considered a hypoplastic pancreatic disorder, longitudinal studies have proven that PAA is the culmination of a lymphocytic immune-mediated inflammatory process.Exocrine pancreatic enzymes provide essential digestive functions such that loss of 90% of this capacity leads to maldigestion and exocrine pancreatic insufficiency (EPI) syndrome. Subclinical and clinical EPI syndromes have been characterized in dogs and are relatively rare in cats. Dogs with subclinical EPI have clinical signs masked by continued small-volume pancreatic enzyme secretion or digestion facilitated by alternative mechanisms (lingual or gastric lipases, gastric pepsins, intestinal mucosal esterases, and peptidases). Causes of canine EPI include pancreatic acinar atrophy (PAA; an apparent autoimmune lymphocytic inflammatory disorder), chronic pancreatitis, and pancreatic neoplasia. By far, PAA is most common and can affect dogs within the first year of life, although it usually becomes overt within the first 3 years. Long considered a hypoplastic pancreatic disorder, longitudinal studies have proven that PAA is the culmination of a lymphocytic immune-mediated inflammatory process.

Lead Causes Of Acid Reflux 10 Remedies (☑ Diagnosis) | Lead Causes Of Acid Reflux Doesn't Helphow to Lead Causes Of Acid Reflux for Inherited PAA is not rare and has been intensively studied in German Shepherd Dogs and Rough-Coated Collie dogs in Finland, where 70% of dogs with EPI are German Shepherd Dogs and 20% are Rough-Coated Collies. A breed prevalence rate of 1% is reported. Although an autosomal recessive mode of inheritance has been proposed in German Shepherd Dogs, the trait may be polygenic or have incomplete penetrance. Accurate recognition of PAA as a syndrome requires acknowledgment that it also can represent the end result of pancreatic duct obstruction, ischemic tissue injury, toxicity, various nutritional deficiencies or imbalances, or defective secretory or trophic stimuli.

Clinical signs of PAA are variable but largely dominated by polyphagia, weight loss, excessive flatulence and borborygmi, and frequent, soft voluminous feces. However, some dogs vomit, some are inappetent, some are overweight, and rarely some dogs are hyperexcitable or aggressive. Progression of subclinical to clinical PAA varies widely; some dogs progress to full clinical disease within weeks, and others have slow progressive disease that never matures. At end-stage PAA, the pancreas is grossly diminished in size, thin, and transparent, with obvious ducts. Owing to the lymphocytic inflammatory lesion, the disorder has been more precisely labeled atrophic lymphocytic pancreatitis. Immunophenotyping has confirmed that CD3-positive T lymphocytes are involved with acinar destruction; histologic features mirror those associated with lymphocytic thyroiditis.

Routine clinical pathologic tests are not informative in most dogs with EPI. Serum ALT may be mild to moderately increased, reflecting uptake of noxious material from the small intestinal tract. Total lipid and cholesterol concentrations are usually low, whereas total protein, albumin, and globulin concentrations are usually normal. Serum activity of amylase and lipase is not informative. Serum the 1 last update 07 Jul 2020 canine trypsin-like immunoreactivity (cTLI) is the distinguishing test for EPI; the test is species- and pancreas-specific, measuring only pancreatic trypsin and trypsinogen that have entered the bloodstream directly from the pancreas. Healthy dogs have cTLI activity greater than 5.0 µg/L, whereas values less than 2.5 µg/L are diagnostic for EPI. Assessment of fasting cTLI values is recommended because even a transient postprandial increase of serum trypsinogen concentration can confuse test interpretation. Renal dysfunction also can obfuscate test interpretation because trypsinogen is eliminated by glomerular filtration. Low serum cTLI concentrations (<5.0 µg/L) on repeated tests can be used to detect subclinical PAA before overt EPI maldigestion can be recognized. Some dogs with minimal clinical signs have cTLI activity as low as others with end-stage PAA. Repeated cTLI measurements may be necessary to confirm subclinical PAA; the lower the cTLI value, the more certain the diagnosis. Notably, some dogs developing PAA have borderline low normal cTLI values. Although pancreatic biopsies can be safely collected, they are not recommended for early diagnosis of PAA because the pathologic process is unevenly distributed. Ultrasonographic diagnosis of PAA also is unreliable.Routine clinical pathologic tests are not informative in most dogs with EPI. Serum ALT may be mild to moderately increased, reflecting uptake of noxious material from the small intestinal tract. Total lipid and cholesterol concentrations are usually low, whereas total protein, albumin, and globulin concentrations are usually normal. Serum activity of amylase and lipase is not informative. Serum canine trypsin-like immunoreactivity (cTLI) is the distinguishing test for EPI; the test is species- and pancreas-specific, measuring only pancreatic trypsin and trypsinogen that have entered the bloodstream directly from the pancreas. Healthy dogs have cTLI activity greater than 5.0 µg/L, whereas values less than 2.5 µg/L are diagnostic for EPI. Assessment of fasting cTLI values is recommended because even a transient postprandial increase of serum trypsinogen concentration can confuse test interpretation. Renal dysfunction also can obfuscate test interpretation because trypsinogen is eliminated by glomerular filtration. Low serum cTLI concentrations (<5.0 µg/L) on repeated tests can be used to detect subclinical PAA before overt EPI maldigestion can be recognized. Some dogs with minimal clinical signs have cTLI activity as low as others with end-stage PAA. Repeated cTLI measurements may be necessary to confirm subclinical PAA; the lower the cTLI value, the more certain the diagnosis. Notably, some dogs developing PAA have borderline low normal cTLI values. Although pancreatic biopsies can be safely collected, they are not recommended for early diagnosis of PAA because the pathologic process is unevenly distributed. Ultrasonographic diagnosis of PAA also is unreliable.

Treatment of clinical EPI requires pancreatic enzyme supplementation for the life of the patient. Most clinicians prefer powdered enzymes (pancrelipase) that are easily mixed with food: 3 g/meal for a 20- to 35-kg dog. Efficacy of enteric-coated enzyme tablets remains unsubstantiated; some studies suggest lower response rates and others no difference from powdered enzymes. However, tablet efficacy may be compromised by gastric retention. Rapid response to enzyme supplementation is usually evident during the first few weeks (weight gain, improved fecal consistency, and reduced flatulence and steatorrhea). Preincubation of digestive enzymes in food before feeding and supplementation with bile salts or antacids have no proven efficacy. Inhibition of gastric acid secretion with H2 blockers remains controversial and is only recommended when response to enzyme therapy is suboptimal or inconsistent. Titrating the amount of supplemental enzymes mixed in food has been advocated by some clinicians but remains controversial. Too large a dose of powdered enzymes in food has been associated with oral bleeding that resolves on dose reduction.

Lead Causes Of Acid Reflux How To Get Rid (☑ Heartburn Relief Foods) | Lead Causes Of Acid Reflux Treatmenthow to Lead Causes Of Acid Reflux for Although diet modifications including low fat, high fiber, and low residue formulations have been recommended for dogs with EPI, studies have demonstrated wide variability in clinical responses among dogs. A highly digestible, low fiber, and moderate/low fat maintenance diet is recommended as the initial choice. Focus on individual patient needs and response to dietary changes and avoidance of radical dietary recommendations are prudent. The goal of diet modification coupled with responsible enzyme supplementation is reduced flatulence, borborygmi, fecal volume, and defecation frequency. Although a low fat diet may be useful during initial treatment, no long-term benefit has been demonstrated.

Dogs with subclinical PAA do not require treatment. However, dogs with partial PAA showing chronic intermittent gastrointestinal signs should receive a clinical trial of supplemental enzyme therapy. Patients with clinical PAA showing persistent signs despite enzyme replacement require a full diagnostic evaluation for inflammatory bowel disease or treatment for small intestinal bacterial overgrowth (SIBO). It is well acknowledged that EPI may be associated with secondary problems including SIBO, low cobalamin concentrations, and coexistent inflammatory bowel disease. Genesis of SIBO is attributed to loss of bacteriostatic factors normally supplied by pancreatic secretions and to greater availability of undigested enteric substrates that allow development of SIBO. Some evidence suggests that pancreatic enzyme replacement alone or administration of tylosin can abate SIBO. In SIBO, low cobalamin concentrations are proposed to reflect bacterial vitamin sequestration or failure to degrade nonintrinsic factor proteins (R proteins) that bind luminal cobalamin. Low cobalamin concentrations also may reflect deficient for 1 last update 07 Jul 2020 production of pancreatic intrinsic factor as a result of acinar atrophy. In one study of dogs with EPI, cobalamin concentrations were low in 82%; a smaller subset had severe hypocobalaminemia (<100 ng/L), which seemingly functioned as a negative prognostic indicator (i.e., shortened survival). Parenteral cobalamin administration is necessary in dogs with subnormal cobalamin concentrations; such treatment is inexpensive and safe, and a good response can be expected in 60% of treated dogs (one study). High folate concentrations, consistent with enteric microbial folate synthesis, have been documented in 37% of dogs with EPI (one study). Although SIBO has been anecdotally linked with EPI, this syndrome remains controversial, and neither high serum folate nor low serum cobalamin concentrations can accurately confirm its presence. Suspected SIBO does not predict favorable response to antibacterial therapy.Dogs with subclinical PAA do not require treatment. However, dogs with partial PAA showing chronic intermittent gastrointestinal signs should receive a clinical trial of supplemental enzyme therapy. Patients with clinical PAA showing persistent signs despite enzyme replacement require a full diagnostic evaluation for inflammatory bowel disease or treatment for small intestinal bacterial overgrowth (SIBO). It is well acknowledged that EPI may be associated with secondary problems including SIBO, low cobalamin concentrations, and coexistent inflammatory bowel disease. Genesis of SIBO is attributed to loss of bacteriostatic factors normally supplied by pancreatic secretions and to greater availability of undigested enteric substrates that allow development of SIBO. Some evidence suggests that pancreatic enzyme replacement alone or administration of tylosin can abate SIBO. In SIBO, low cobalamin concentrations are proposed to reflect bacterial vitamin sequestration or failure to degrade nonintrinsic factor proteins (R proteins) that bind luminal cobalamin. Low cobalamin concentrations also may reflect deficient production of pancreatic intrinsic factor as a result of acinar atrophy. In one study of dogs with EPI, cobalamin concentrations were low in 82%; a smaller subset had severe hypocobalaminemia (<100 ng/L), which seemingly functioned as a negative prognostic indicator (i.e., shortened survival). Parenteral cobalamin administration is necessary in dogs with subnormal cobalamin concentrations; such treatment is inexpensive and safe, and a good response can be expected in 60% of treated dogs (one study). High folate concentrations, consistent with enteric microbial folate synthesis, have been documented in 37% of dogs with EPI (one study). Although SIBO has been anecdotally linked with EPI, this syndrome remains controversial, and neither high serum folate nor low serum cobalamin concentrations can accurately confirm its presence. Suspected SIBO does not predict favorable response to antibacterial therapy.

Testing for PAA using low serum trypsin–like immunoreactivity (sTLI) as a defining marker has permitted early diagnosis of dogs with subclinical disease. Nevertheless, immunomodulation during this stage cannot be advocated because of the slow onset of full PAA in some dogs and because some dogs with PAA remain asymptomatic for their lifetime. Because dietary sensitivities may complicate EPI, hypoallergenic diets may benefit some dogs during early treatment. Although some clinicians have used medium-chain triglycerides to increase the energy value of foods fed to undernourished EPI patients, benefit of this strategy remains unproven. The typical gastrointestinal signs of EPI are almost completely eliminated in nearly 50% of treated dogs. Poor responses are realized in approximately 20% of dogs (continued diarrhea, unthrifty appearance, and flatulence), and many of these are euthanized during the first year of diagnosis. Dogs failing to respond to treatment do not make good house pets. Unfortunately the high cost of enzyme supplements also has led to euthanasia of some dogs. At present, there is no evidence that combinations of antimicrobials, H2 blockers, or powder versus tablet enzyme formulations improve response and/or survival in symptomatic dogs. Generally the long-term prognosis is good for dogs that survive the initial treatment interval. Although mesenteric torsion has been noted as a severe complication of EPI in German Shepherd Dogs, this complication has decreased in frequency with improved treatment regimens and enzyme preparations.

Read full chapter
URL: https://www.sciencedirect.com/science/article/pii/B9781416048893000371